US20100215655A1 - Angiogenesis-inhibiting chimeric proteins and the use - Google Patents
Angiogenesis-inhibiting chimeric proteins and the use Download PDFInfo
- Publication number
- US20100215655A1 US20100215655A1 US12/773,315 US77331510A US2010215655A1 US 20100215655 A1 US20100215655 A1 US 20100215655A1 US 77331510 A US77331510 A US 77331510A US 2010215655 A1 US2010215655 A1 US 2010215655A1
- Authority
- US
- United States
- Prior art keywords
- flt
- domain
- kdrd3
- fltd2
- designated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to gene engineering technology, more specifically to DNA sequences encoding angiogenesis-inhibiting recombinant chimeric proteins, the encoded chimeric proteins herein, therapeutic applications thereof, medical composition and formulation containing the chimeric proteins.
- Angiogenesis is a process of growing new blood vessels from existing blood vessels. Most adult vascular system is quiescence, angiogenesis only occurs in some physiological and pathological mechanisms, such as tumor, diabetic retinopathies, arthritis, anemia organs, endometrial hyperplasia, etc. Angiogenesis plays key roles in rapid growth of tumor cells during tumor development (Hanahan and Folkman: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 1996, 86:353-364). Studies of animal cancer models and human clinical trials have already proved that inhibition of tumor angiogenesis could effectively inhibit tumor growth and development, therefore prolong patient's life. Angiogenesis is mediated and regulated by many biological factors.
- Main cells mediating angiogenesis are vascular endothelial cells that form the inside wall of blood vessels.
- Various growth factors can bind to relevant receptors on the surface of vascular endothelial cells, regulate cellular processes via intracellular signal transduction, and therefore mediate angiogenesis.
- VEGF vascular endothelial cell growth factor
- FLT-1 FLT-1 (fms-like tyrosine kinase)
- KDR KDR
- these two receptors both consist of three different functional regions: the first region is the extracellular region, consisting of seven immunoglobulin-like (Ig-like) domains (d1-d7), which has specific affinity to VEGF, and is the key region for binding VEGF; the second region is the trans-membrane region containing hydrophobic amino acid residues; the third region is the intracellular domain that contains tyrosine kinase functioning group, which gets phosphorylated after the receptor is activated by VEGF, triggering the intracellular signal transduction, leading to functional effects of endothelial cells and angiogenesis.
- Ig-like domains Ig-like domains
- FLT-1 and KDR are mainly distributed in vascular endothelial cells.
- VEGF's mediating activity to vascular endothelial cells is highly specific.
- VEGF promotes endothelial cell differentiations, guides endothelial cell migrations, inhibits apoptosis, induces vascular morphological changes, and is a highly effective pro-angiogenesis factor.
- VEGF vascular endothelial growth factor
- VEGF vascular endothelial growth factor
- the soluble KDR was also able to inhibit growth of vascular endothelial cells in vitro, but its anti-tumor activity in animal models was not satisfactory (Yoko Hasumi: Soluble FLT-1 Expression Suppresses Carcinomatous Ascites in Nude Mice Bearing Ovarian Cancer. Cancer Research 62, 2002: 2019-2023).
- the present invention provides novel chimeric proteins containing different fragments of FLT-1 and KDR to effectively block the biological activity of VEGF and inhibit angiogenesis.
- the first aspect of the invention is to provide novel recombinant chimeric proteins that block the biological activity of VEGF and inhibit angiogenesis.
- the second aspect of the invention is to provide DNA sequences encoding the above-mentioned chimeric proteins.
- the third aspect of the invention is to provide vectors containing the coding DNA sequences of the chimeric proteins and recombinant hosts thereof.
- the fourth aspect of the invention is to provide the use of the chimeric proteins in preparing medicaments that block the VEGF activity and inhibit angiogenesis, and medical composition containing the chimeric proteins and appropriate medical carriers and dosage form thereof, as well as therapeutic applications of the medical composition.
- Key points of the invention are to design and construct a series of chimeric proteins with different FLT-1 or KDR fragments, which preferably contain human immunoglobulin Fc (construction method is shown in FIG. 1 ), and then to select the chimeric protein with high affinity to VEGF using assays including the VEGF binding assay, and finally to obtain the proper VEGF inhibitor.
- Construction of the chimeric protein is based on the conventional molecular cloning technologies. Detailed experimental methodology could be found in laboratory manuals such as Molecular Cloning, the 2 nd or the 3 rd edition (Joseph Sambrook).
- the chimeric proteins made via recombinant DNA technology contain different fragments of the VEGF receptors FLT-1 and KDR, wherein the chimeric proteins are selected from the following groups:
- the amino acid sequence of FLTd2 is shown as SEQ ID NO.1.
- the amino acid sequence of FLTd4 is shown as SEQ ID NO.2.
- the amino acid sequence of KDRd1 is shown as SEQ ID NO.3.
- the amino acid sequence of KDRd3 is shown as SEQ ID NO.4.
- the amino acid sequence of KDRd4 is shown as SEQ ID NO.5.
- FLT refers to the FLT-1 sequence
- KDR refers to the KDR sequence
- di refers to the i th Ig-like domain in FLT-1 or KDR.
- the present invention provides a class of chimeric proteins that contain human immunoglobulin Fc, and are preferably selected from the following groups:
- FP3′ designated as FLTd2-KDRd3,4-Fc
- FP4′ designated as FLTd2-KDRd3-FLTd4-Fc;
- FP5′ designated as FLTd2-KDRd3,4,5-Fc;
- FP6′ designated as FLTd2-KDRd3-FLTd4,5-Fc.
- Fc refers to the human immunoglobulin Fc fragment derived from human immunoglobulin FC such as IgG, IgM, and IgA, or subclasses IgG1, IgG2, IgG3, and IgG4.
- the Fc region can be the full length Fc sequence or a fragment of the Fc sequence from CH2, CH3, or the hinge region.
- the chimeric protein known in the prior art (designated as FP1′) consists of the 2 nd Ig-like domain of FLT-1 (FLTd2), the 3 rd Ig-like domain of KDR (KDRd3), and the human immunoglobulin Fc.
- the chimeric protein FP2′ provided in the invention has added amino acid sequence of the 1 st Ig-like domain of KDR (KDRd1) into FP1′, which increases binding sites for VEGF and enhances affinity to VEGF.
- the chimeric proteins FP3′ and FP4′ have added sequences of the 4 th Ig-like domain of KDR (KDRd4) or the 4 th Ig-like domain of FLT-1 (FLTd4) based on FP1′, respectively.
- FP5′ and FP6′ have added the 4 th and the 5 th Ig-like domains of KDR (KDRd4, 5) and the 4 th and the 5 th Ig-like domains of FLT-1 (FLT-1d4, 5) based on FP1′, respectively.
- the present invention provides a chimeric protein FP3′ with amino acid sequence shown as SEQ ID NO.7.
- the chimeric proteins described in the invention can be obtained through conventional recombinant DNA technologies.
- recombinant DNA coding sequences of the above mentioned chimeric proteins could be obtained, wherein the coding DNA sequences of FLT-1 and KDR are available in GenBank, NCBI (National Center for Biotechnology Information).
- the DNA coding sequences of the above-mentioned chimeric proteins are cloned into vectors after PCR synthesis.
- the vectors herein could be commonly used plasmids, viruses, or DNA fragments in molecular biology.
- Secretory signal sequence is inserted into the terminal of the DNA sequence of the aforesaid chimeric peptides to ensure secretion out of cells.
- the vector sequence includes a promoter region that enables gene transcription, starting and stopping signals for protein translation, and a polyA sequence.
- the vector contains an antibiotics resistant gene for propagation in bacteria.
- the vector contains a eukaryotic cell selection gene for selection of stable transfected cell lines.
- the plasmids could be used to transfect host cells to express the chimeric proteins.
- these chimeric proteins including (but not limited to) mammalian cells, bacteria, yeast, and insect cells.
- mammalian and insect cells are eukaryotic cells
- bacteria and yeast cells are prokaryotic cells.
- Proteins expressed from mammalian cells are glycosylated. Since the chimeric proteins of the invention contain glycosylation sites, mammalian cells are the best cells to express them.
- Plasmids encoding the above-mentioned chimeric proteins could be transfected into the cells. Methods of transfection include, but not limited to, electroporation, liposome-mediated transfection, Calcium precipitation, and etc.
- Expression systems other than mammalian cells could also be used to express these chimeric proteins, such as bacteria, yeast, insect cells, and etc. They should all be considered as within the scope of the invention. These expression systems have a higher protein production yield comparing with that of mammalian cells, however, they produce proteins with no glycosylation or with carbohydrate chains glycosylated different from that of mammalian cells.
- the chimeric proteins concentrations in the cell culture media could be measured by ELISA or other assays. Since the chimeric proteins contain the immunoglobulin Fc region, they could be purified using Protein A affinity chromatography.
- chimeric proteins After various chimeric proteins were obtained from culture media of the recombinant host cells, they were assayed in VEGF binding experiments to compare their affinities to VEGF. Their VEGF inhibition activities were further assayed in a VEGF-induced human vascular endothelial cell proliferation experiment.
- the experimental results have shown that all chimeric proteins constructed according to the present invention can bind to VEGF with high affinities ( FIG. 2 ), comparing with the FP1′ of the prior art. In addition, they could effectively block the VEGF activation of the vascular endothelial cells and inhibit growth of the endothelial cells. Further experiments have shown that FP3′ has the best blocking activity on VEGF and is the most effective VEGF-blocking chimeric proteins of the invention.
- the chimeric proteins constructed in the invention have supreme blocking activities on VEGF, and all have biological activities of anti-angiogenesis, therefore can be used to treat angiogenesis or VEGF related diseases, including but not limited to various tumor, diabetic retinopathies, arthritis, anemia, endometrial hyperplasia, etc.
- the present invention also provides medical compositions comprising the above-described chimeric proteins and appropriate medical carriers.
- Said compositions can be formulated into any dosage forms according to conventional formulation methodologies, preferably into a dosage form for injection, and more preferably into a lyophilized format.
- FIG. 1 shows the structures of the five chimeric proteins according to a preferred embodiment of the invention and FP1′ of the prior art. They are constructed with different fragments from FLT-1, KDR and the immunoglobulin Fc region using genic engineering technologies.
- FIG. 2 exhibits the results of VEGF binding of the five chimeric proteins in a preferred embodiment of the invention, in comparison with that of FP1′ of the prior art, wherein OD readings refer to the binding signals of chimeric proteins to VEGF.
- the results have shown that all the five chimeric proteins bound to VEGF with much higher affinities than FP1′, among them, FP3′ has the highest affinity.
- FIG. 3 shows that the chimeric proteins of the invention could effectively inhibit human vascular endothelial cell growth in vitro, in comparison with FP1′.
- FIG. 4 shows that the chimeric protein FP3 could effectively inhibit B16F10 melanoma tumor growth in mice.
- FIG. 5 shows that the chimeric protein FP3′ could effectively inhibit human PC-3 prostate tumor growth in mice.
- FIG. 6 compares anti-tumor growth activities of the chimeric protein FP3′ of the invention with that of FP1′ of the prior art in mice.
- coding DNA sequences of the various chimeric proteins of the invention come from cDNAs of FLT-1 and KDR. Since FLT-1 and KDR are mainly expressed in vascular endothelial cells, the total RNA were extracted from human umbilical vein endothelial cells (HUVEC) using a RNA purification kit (QIAGEN); then cDNAs were synthesized from the RNA using AMV Reverse Transcriptese (Promega); then various FLT-1 and KDR fragments were PCR amplified with different primers; finally the sequences from FLT-1, KDR, and human immunoglobulin Fc (IgG1 Fc) were fused together by PCR to construct recombinant DNA sequences encoding various chimeric proteins. Structures of all six chimeric proteins (including FP1′ of the prior art) are shown in FIG. 1 .
- HUVEC cells (Clonetics) were cultured with EGM-2 media (Clonetics) in T-175 flasks. 1 ⁇ 10 7 cells were collected and subjected to the total RNA extraction using the RNA purification kit from Qiagen, and then cDNA was synthesized using the Invitrogen cDNA kit. The cDNA product was stored at ⁇ 80° C. until usage.
- PCR utilizing specific primers were used to amplify various FLT-1 and KDR domains from the HUVEC cDNA. Likewise, PCR utilizing specific primers from Lymph Nodes cDNA (BD Clontech) were used to amplify human IgG1 Fc was PCR.
- the Ig-like domains and the human IgG1 Fc fragment were PCR amplified at conditions of denaturing at 95° C. for 30 seconds, annealing at 56° C. for 45 seconds, extension at 72° C. for 2 minutes, and 30 cycles.
- the PCR products were then cloned into plasmid pCR2.1 (Invitrogen) using the TA cloning kit. After transformation into E.coli (JM109), white colonies were picked and cultured overnight in LB media.
- DNA plasmids were prepared using the Qiagen kit and subjected to enzyme digestion and DNA sequencing.
- the cDNAs of FLT-1, KDR and IgG Fc were fused together by sewing PCR using primers containing the EcoRI site. After digestion with EcoRI, the DNA fragment was purified with the Qiagen purification kit and cloned into plasmid pcDNA3.1. After transformed into E. coli (JM109), positive colonies were picked and cultured overnight in LB media. DNA plasmids were extracted with the Qiagen plasmid purification kit and then subjected to enzyme digestion and DNA sequencing. The obtained FP3′ DNA coding sequence is shown as SEQ ID NO.6. The confirmed plasmids were used to transfect 293 cells or CHO cells to obtain stable cell lines expressing FP3′. The amino acid sequence of FP3′ is shown as SEQ ID NO.7.
- FP1′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2 nd Ig-like domain of FLT-1, the 3 rd Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP2′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 1 st Ig-like domain of KDR, the 2 nd Ig-like domain of FLT-1, the 3 rd Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP4′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2 nd Ig-like domain of FLT-1, the 3 rd Ig-like domain of KDR, the 4 th Ig-like domain of FLT-1, and the same human IgG1 Fc as in Example 1.
- FP5′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2 nd Ig-like domain of FLT-1, the 3 rd -5 th Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP6′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2 nd Ig-like domain of FLT-1, the 3 rd Ig-like domain of KDR, the 4 th -5 th Ig-like domain of FLT-1, and the same human IgG1 Fc as in Example 1.
- the first method was a method of transient transfection. A small amount of the chimeric proteins were produced using this method. Firstly, 293 cells were cultured in DMEM media with 10% FBS in tissue culture dishes. At 60-80% cell confluence, the mixture of plasmid DNA and FUGEN6 reagent was added into the culture. The culture media was exchanged to serum-free DMEM in the next day and the cells were continued to culture for 3 more days before media was collected. These media contained the expressed chimeric proteins, and the concentration of the chimeric proteins was assayed by ELISA.
- the second method was a method of stable transfection.
- a stable cell line was established to produce a large amount of the chimeric proteins.
- the host cells were again 293 cells (ATCC).
- the step of transfecting recombinant plasmid was the same as that of transient transfection described above. However, at the 2 nd day, the cells were cultured in DMEM with neomycin and cloned by limited dilution. After about 21 days, neomycin resistant clones were picked and cultured in a larger scale. Finally, chimeric proteins were expressed in shaker flasks. The concentration of chimeric proteins was assayed by ELISA.
- FP3′ was purified from the cultured media using assays including affinity chromatography and gel filtration, etc.
- the molecular weight of FP3′ was 140 KD.
- Chimeric proteins FP1′, FP2′, FP4′, FP5′, and FP6′ were obtained in accordance with the methods of example 7.
- Affinities of the chimeric proteins to VEGF were determined by the VEGF binding assay in the present invention. Firstly, recombinant VEGF proteins (Chemicom) were coated in a 96-well ELISA plate, and non-specific protein binding sites of the plate were then blocked using 5% milk solution. Secondly, different concentrations of various chimeric proteins were added into each well, and incubated for 2 hours at 37° C. After washing, rabbit anti-human Ig-HRP (Sigma) was added into each well, and finally colorimetric enzyme substrates were added to the plate. The absorption OD readings were recorded with the use of an ELISA plate reader. A higher OD value indicated a stronger binding affinity of the chimeric proteins to VEGF.
- FP3′ had the best affinity and was the best VEGF inhibitor. Its half maximal binding concentration was about 5 times lower than that of FP1′.
- FP5′ had a little bit lower affinity to VEGF than that of FP3′. This result suggests that the 4 th Ig-like domain of KDR could substantially increase the blocking activity of the chimeric protein to VEGF.
- This preferred embodiment of the invention is to prove that the chimeric proteins could effectively block VEGF-induced growth of vascular endothelial cells.
- HUVEC cells (Clonetics) were seeded in a 96-well tissue culture plate in EBM media with 2% FBS and 15 ng/ml of VEGF. Different amounts of the 293 cells supernatant containing the chimeric proteins were added into the plate. Un-transfected 293 cells media containing no chimeric proteins was used as negative control. All HUVEC cells were cultured in 37° C. for 3 days before cell densities were determined by cell counting.
- the HUVEC proliferation experiment has shown that all five chimeric proteins constructed according to the invention could inhibit proliferation of vascular endothelial cells more effectively than FP1′ of the prior art ( FIG. 3 ). Since the HUVEC cell proliferation in the experiment was induced by VEGF activation, it is therefore suggested that all five chimeric proteins were able to inhibit the receptor activation of VEGF, and all of them possessed anti-angiogenesis activities. Among which, FP3′ had the best inhibiting effect on the HUVEC cell growth with IC50 of about 3 ng/ml. The IC50 of FP1′ of the prior art was about 12 ng/ml, and the IC50s of FP2′, FP4′, FP5′ and PF6′ were all about 5-8 ng/ml.
- the injection formulation was prepared according to any conventional methodologies, for injection formulations using 24 mg/ml of FP3′, 5 mM of PB, 100 mM of NaCl, and 20% sucrose.
- VEGF inhibitors As VEGF inhibitors, one application of the chimeric proteins of the invention is to be used in anti-cancer therapy. Because of its highly effective blocking effect on VEGF, FP3′ was chosen to perform anti-tumor experiments in animal models.
- the animal model was murine with B16F10 melanoma cells which is a kind of rapidly growing tumor cells.
- 1 ⁇ 10 5 B16F10 cells in 0.05 ml were first injected subcutaneously in the back of BALB/C nude mice. Then the purified chimeric protein was injected intraperitomneally with 400 ⁇ g each mouse (mice average weight 22 g), twice a week. Same amount of the purified human immunoglobulin Fc was injected into negative control mice. Tumor growth curves were shown in FIG. 4 , indicating that the chimeric protein FP3′ effectively inhibited the growth of the melanoma cells (P ⁇ 0.01).
- Xenograft model of human tumor cells growing in nude mice is one of the animal models, which is most similar with human tumors. Nude mice lack of immune rejection, thus many human tumor cells could grow in nude mice and form tumor.
- the chimeric protein FP3′ was tested for inhibiting growth of human prostate tumor PC-3 cells (ATCC) in BALB/C nude mice. In this model, 1 ⁇ 10 5 PC-3 cells in 0.05 ml were first injected subcutaneously in the back of mice. Then the purified chimeric protein was injected intraperitomneally with 400 ⁇ g each mouse, twice a week. Same amount of the purified human immunoglobulin Fc was injected into negative control mice. The experimental results were shown in FIG. 5 .
- FP1′ and FP3′ were compared in a tumor growth experiment.
- 10 healthy BALB/C nude mice were chosen and each was injected subcutaneously in the back with 1 ⁇ 10 5 rat glioblastoma C6 cells in 0.05 ml.
- 2.5 mg/kg of purified PF1′ or PF3′ were injected intraperitomneally twice a week, respectively, up to 31 days.
- the same amount of the purified human immunoglobulin Fc was injected into negative control mice.
- the experimental results are shown in FIG. 6 .
- FP1′ and FP3′ both had a significant therapeutic effect on the tumor.
- the chimeric proteins constructed according to the invention had a high affinity to VEGF, were able to inhibit vascular endothelial cell proliferation in vitro, and effectively inhibited tumor growth in vivo. Since angiogenesis is critical in all tumor growth, the chimeric proteins of the invention can be used in therapeutic applications against many tumors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
The present invention is directed to DNA sequence encoding angionenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.
Description
- This application is a divisional application of U.S. patent application Ser. No. 11/628,735 filed Dec. 7, 2006, which was filed under 35 U.S.C. 371 as a national stage of PCT/CN2005/000802, with an international filing date of Jun. 8, 2005, and claims priority to patent application CN 200410044965.7 filed Jun. 8, 2004, the content of each of which is hereby incorporated by reference in its entirety.
- The present invention relates to gene engineering technology, more specifically to DNA sequences encoding angiogenesis-inhibiting recombinant chimeric proteins, the encoded chimeric proteins herein, therapeutic applications thereof, medical composition and formulation containing the chimeric proteins.
- Angiogenesis is a process of growing new blood vessels from existing blood vessels. Most adult vascular system is quiescence, angiogenesis only occurs in some physiological and pathological mechanisms, such as tumor, diabetic retinopathies, arthritis, anemia organs, endometrial hyperplasia, etc. Angiogenesis plays key roles in rapid growth of tumor cells during tumor development (Hanahan and Folkman: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 1996, 86:353-364). Studies of animal cancer models and human clinical trials have already proved that inhibition of tumor angiogenesis could effectively inhibit tumor growth and development, therefore prolong patient's life. Angiogenesis is mediated and regulated by many biological factors. Main cells mediating angiogenesis are vascular endothelial cells that form the inside wall of blood vessels. Various growth factors can bind to relevant receptors on the surface of vascular endothelial cells, regulate cellular processes via intracellular signal transduction, and therefore mediate angiogenesis.
- Among various growth factors, VEGF (vascular endothelial cell growth factor) is the most important angiogenesis factor (Ferrara: VEGF and the quest for tumor angiogenesis factor, Nat. Rev. Cancer, 2002, 10: 795-803; Ferrara: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications, Semin. Oncol., 2002, 29 (6 sumppl): 10-14). VEGF could be secreted by many types of cells, but often over-expressed in tumor cells. VEGF functions by binding to appropriate receptors. There are mainly two kinds of VEGF receptors: FLT-1 (fms-like tyrosine kinase) and KDR. In terms of molecular structures, these two receptors both consist of three different functional regions: the first region is the extracellular region, consisting of seven immunoglobulin-like (Ig-like) domains (d1-d7), which has specific affinity to VEGF, and is the key region for binding VEGF; the second region is the trans-membrane region containing hydrophobic amino acid residues; the third region is the intracellular domain that contains tyrosine kinase functioning group, which gets phosphorylated after the receptor is activated by VEGF, triggering the intracellular signal transduction, leading to functional effects of endothelial cells and angiogenesis.
- FLT-1 and KDR are mainly distributed in vascular endothelial cells. Thus, VEGF's mediating activity to vascular endothelial cells is highly specific. VEGF promotes endothelial cell differentiations, guides endothelial cell migrations, inhibits apoptosis, induces vascular morphological changes, and is a highly effective pro-angiogenesis factor.
- The expression level of VEGF in tumor tissues is higher than that in the normal tissues. In addition, rapid growth of tumor cells often leads to hypoxia inside the tumor, and hypoxia further induces expression of VEGF. Thus, VEGF is the key factor promoting tumor angiogenesis. Many animal studies have shown that inhibiting binding of VEGF to its receptors could effectively inhibit tumor angiogenesis, and therefore inhibit tumor growth. In other angiogenesis-related diseases, such as diabetic retinopathies and arthritis, etc, VEGF is also closely involved in the development of these diseases (Ferrara: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 2002, 29 (6 sumppl): 10-14).
- Because of the critical roles of VEGF in cancers and other diseases, proteins or chemicals that specifically inhibit VEGF have therapeutic potentials. For example, studies have shown that neutralizing antibody against VEGF could effectively inhibit tumor growth (Jain: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor, Semin. Oncol., 2002, 29 (6 suppl): 3-9). Therefore, developing novel effective VEGF inhibitors is important in clinical research. Since FLT-1 and KDR are natural binders of VEGF, there were studies that investigated the anti-angiogenesis roles of the soluble FLT-1 (the extracellular domain of FLT-1) and the soluble KDR (the extracellular domain of KDR) (Yoko Hasumi: Soluble FLT-1 Expression Suppresses Carcinomatous Ascites in Nude Mice Bearing Ovarian Cancer. Cancer Research 62, 2002: 2019-2023). The soluble FLT-1 could effectively inhibit growth of vascular endothelial cells in vitro, but it has a short serum half-life and can not reach effective serum concentration. Similarly, the soluble KDR was also able to inhibit growth of vascular endothelial cells in vitro, but its anti-tumor activity in animal models was not satisfactory (Yoko Hasumi: Soluble FLT-1 Expression Suppresses Carcinomatous Ascites in Nude Mice Bearing Ovarian Cancer. Cancer Research 62, 2002: 2019-2023).
- To overcome the shortcomings of the prior art, the present invention provides novel chimeric proteins containing different fragments of FLT-1 and KDR to effectively block the biological activity of VEGF and inhibit angiogenesis.
- The first aspect of the invention is to provide novel recombinant chimeric proteins that block the biological activity of VEGF and inhibit angiogenesis.
- The second aspect of the invention is to provide DNA sequences encoding the above-mentioned chimeric proteins.
- The third aspect of the invention is to provide vectors containing the coding DNA sequences of the chimeric proteins and recombinant hosts thereof.
- The fourth aspect of the invention is to provide the use of the chimeric proteins in preparing medicaments that block the VEGF activity and inhibit angiogenesis, and medical composition containing the chimeric proteins and appropriate medical carriers and dosage form thereof, as well as therapeutic applications of the medical composition.
- Key points of the invention are to design and construct a series of chimeric proteins with different FLT-1 or KDR fragments, which preferably contain human immunoglobulin Fc (construction method is shown in
FIG. 1 ), and then to select the chimeric protein with high affinity to VEGF using assays including the VEGF binding assay, and finally to obtain the proper VEGF inhibitor. Construction of the chimeric protein is based on the conventional molecular cloning technologies. Detailed experimental methodology could be found in laboratory manuals such as Molecular Cloning, the 2nd or the 3rd edition (Joseph Sambrook). - According to the present invention, the chimeric proteins made via recombinant DNA technology contain different fragments of the VEGF receptors FLT-1 and KDR, wherein the chimeric proteins are selected from the following groups:
-
- a. Consisting of the 1st Ig-like domain of KDR, the 2nd Ig-like domain of FLT-1, and the 3rd Ig-like domain of KDR, designated as KDRd1-FLTd2-KDRd3;
- b. Consisting of the 2nd Ig-like domain of FLT-1, and the 3rd and the 4th Ig-like domains of KDR, designated as FLTd2-KDRd3,4;
- c. Consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th Ig-like domain of FLT-1, designated as FLTd2-KDRd3-FLTd4;
- d. Consisting of the 2nd Ig-like domain of FLT-1, and the 3rd, the 4th and the 5th Ig-like domains of KDR, designated as FLTd2-KDRd3,4,5;
- e. Consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th and the 5th Ig-like domains of FLT-1, designated as FLTd2-KDRd3-FLTd4,5.
- The amino acid sequence of FLTd2 is shown as SEQ ID NO.1. The amino acid sequence of FLTd4 is shown as SEQ ID NO.2. The amino acid sequence of KDRd1 is shown as SEQ ID NO.3. The amino acid sequence of KDRd3 is shown as SEQ ID NO.4. The amino acid sequence of KDRd4 is shown as SEQ ID NO.5.
- As used herein, FLT refers to the FLT-1 sequence, KDR refers to the KDR sequence; di refers to the ith Ig-like domain in FLT-1 or KDR.
- Preferably, the present invention provides a class of chimeric proteins that contain human immunoglobulin Fc, and are preferably selected from the following groups:
- FP2′ designated as KDRd1-FLTd2-KDRd3-Fc;
- FP3′ designated as FLTd2-KDRd3,4-Fc;
- FP4′ designated as FLTd2-KDRd3-FLTd4-Fc;
- FP5′ designated as FLTd2-KDRd3,4,5-Fc;
- FP6′ designated as FLTd2-KDRd3-FLTd4,5-Fc.
- As used herein, Fc refers to the human immunoglobulin Fc fragment derived from human immunoglobulin FC such as IgG, IgM, and IgA, or subclasses IgG1, IgG2, IgG3, and IgG4. The Fc region can be the full length Fc sequence or a fragment of the Fc sequence from CH2, CH3, or the hinge region.
- As shown in
FIG. 1 , the chimeric protein known in the prior art (designated as FP1′) consists of the 2nd Ig-like domain of FLT-1 (FLTd2), the 3rd Ig-like domain of KDR (KDRd3), and the human immunoglobulin Fc. The chimeric protein FP2′ provided in the invention has added amino acid sequence of the 1st Ig-like domain of KDR (KDRd1) into FP1′, which increases binding sites for VEGF and enhances affinity to VEGF. The chimeric proteins FP3′ and FP4′ have added sequences of the 4th Ig-like domain of KDR (KDRd4) or the 4th Ig-like domain of FLT-1 (FLTd4) based on FP1′, respectively. FP5′ and FP6′ have added the 4th and the 5th Ig-like domains of KDR (KDRd4, 5) and the 4th and the 5th Ig-like domains of FLT-1 (FLT-1d4, 5) based on FP1′, respectively. These added sequences could help dimerization of the chimeric proteins, folding 3-dimentional structures favorable for VEGF binding, and enhancing affinity to VEGF. - More preferably, the present invention provides a chimeric protein FP3′ with amino acid sequence shown as SEQ ID NO.7.
- The chimeric proteins described in the invention can be obtained through conventional recombinant DNA technologies. At first, recombinant DNA coding sequences of the above mentioned chimeric proteins could be obtained, wherein the coding DNA sequences of FLT-1 and KDR are available in GenBank, NCBI (National Center for Biotechnology Information). Secondly, the DNA coding sequences of the above-mentioned chimeric proteins are cloned into vectors after PCR synthesis. The vectors herein could be commonly used plasmids, viruses, or DNA fragments in molecular biology. Secretory signal sequence is inserted into the terminal of the DNA sequence of the aforesaid chimeric peptides to ensure secretion out of cells. The vector sequence includes a promoter region that enables gene transcription, starting and stopping signals for protein translation, and a polyA sequence. The vector contains an antibiotics resistant gene for propagation in bacteria. In addition, the vector contains a eukaryotic cell selection gene for selection of stable transfected cell lines.
- Because there is no absolute boundary of the amino acid sequences of all Ig-like domains in FLT-1 and KDR, the sequence length of these domains could have variations. Thus the sequences of the chimeric proteins described in the invention could have similar variations. It should be appreciated that all of these sequence variants are not to be considered as beyond the scope of the invention.
- After plasmids construction of the above-mentioned chimeric proteins, the plasmids could be used to transfect host cells to express the chimeric proteins. There are many expression systems for these chimeric proteins, including (but not limited to) mammalian cells, bacteria, yeast, and insect cells. Among them, mammalian and insect cells are eukaryotic cells, whereas bacteria and yeast cells are prokaryotic cells. Proteins expressed from mammalian cells are glycosylated. Since the chimeric proteins of the invention contain glycosylation sites, mammalian cells are the best cells to express them. There are many mammalian cell types suitable for large scale protein productions, such as 293 cells, CHO cells, SP20 cells, NS=
b 0 =l cells, COS cells, BHK cells, PerC6 cells, and etc. Many other types of cells could also be used to express and produce these proteins, and they are all within the scope of the invention. Plasmids encoding the above-mentioned chimeric proteins could be transfected into the cells. Methods of transfection include, but not limited to, electroporation, liposome-mediated transfection, Calcium precipitation, and etc. - Expression systems other than mammalian cells could also be used to express these chimeric proteins, such as bacteria, yeast, insect cells, and etc. They should all be considered as within the scope of the invention. These expression systems have a higher protein production yield comparing with that of mammalian cells, however, they produce proteins with no glycosylation or with carbohydrate chains glycosylated different from that of mammalian cells.
- After expression of the chimeric proteins, the chimeric proteins concentrations in the cell culture media could be measured by ELISA or other assays. Since the chimeric proteins contain the immunoglobulin Fc region, they could be purified using Protein A affinity chromatography.
- After various chimeric proteins were obtained from culture media of the recombinant host cells, they were assayed in VEGF binding experiments to compare their affinities to VEGF. Their VEGF inhibition activities were further assayed in a VEGF-induced human vascular endothelial cell proliferation experiment. The experimental results have shown that all chimeric proteins constructed according to the present invention can bind to VEGF with high affinities (
FIG. 2 ), comparing with the FP1′ of the prior art. In addition, they could effectively block the VEGF activation of the vascular endothelial cells and inhibit growth of the endothelial cells. Further experiments have shown that FP3′ has the best blocking activity on VEGF and is the most effective VEGF-blocking chimeric proteins of the invention. - Thus, the chimeric proteins constructed in the invention have supreme blocking activities on VEGF, and all have biological activities of anti-angiogenesis, therefore can be used to treat angiogenesis or VEGF related diseases, including but not limited to various tumor, diabetic retinopathies, arthritis, anemia, endometrial hyperplasia, etc.
- In order to further substantiate the anti-angiogenesis effect of the chimeric proteins in vivo, some animal model experiments have also been made. The results of these experiments have shown that in B16F10 melanoma BALB/C nude mouse model and human PC-3 prostate tumor xenograft mouse model, the chimeric proteins of the invention have been much better than FP1′ of the prior art, and effectively inhibited tumor growth and prolonged animal life. Thus, the chimeric proteins of the invention are of high anti-cancer activities.
- The present invention also provides medical compositions comprising the above-described chimeric proteins and appropriate medical carriers. Said compositions can be formulated into any dosage forms according to conventional formulation methodologies, preferably into a dosage form for injection, and more preferably into a lyophilized format.
-
FIG. 1 shows the structures of the five chimeric proteins according to a preferred embodiment of the invention and FP1′ of the prior art. They are constructed with different fragments from FLT-1, KDR and the immunoglobulin Fc region using genic engineering technologies. -
FIG. 2 exhibits the results of VEGF binding of the five chimeric proteins in a preferred embodiment of the invention, in comparison with that of FP1′ of the prior art, wherein OD readings refer to the binding signals of chimeric proteins to VEGF. The results have shown that all the five chimeric proteins bound to VEGF with much higher affinities than FP1′, among them, FP3′ has the highest affinity. -
FIG. 3 shows that the chimeric proteins of the invention could effectively inhibit human vascular endothelial cell growth in vitro, in comparison with FP1′. -
FIG. 4 shows that the chimeric protein FP3 could effectively inhibit B16F10 melanoma tumor growth in mice. -
FIG. 5 shows that the chimeric protein FP3′ could effectively inhibit human PC-3 prostate tumor growth in mice. -
FIG. 6 compares anti-tumor growth activities of the chimeric protein FP3′ of the invention with that of FP1′ of the prior art in mice. - The following examples provide detailed description of construction, experimental methodology and application of the chimeric proteins described in the invention. But these examples should not be construed to limit the protection scope of the invention.
- Other than the immunoglobulin Fc coding DNA sequence, coding DNA sequences of the various chimeric proteins of the invention come from cDNAs of FLT-1 and KDR. Since FLT-1 and KDR are mainly expressed in vascular endothelial cells, the total RNA were extracted from human umbilical vein endothelial cells (HUVEC) using a RNA purification kit (QIAGEN); then cDNAs were synthesized from the RNA using AMV Reverse Transcriptese (Promega); then various FLT-1 and KDR fragments were PCR amplified with different primers; finally the sequences from FLT-1, KDR, and human immunoglobulin Fc (IgG1 Fc) were fused together by PCR to construct recombinant DNA sequences encoding various chimeric proteins. Structures of all six chimeric proteins (including FP1′ of the prior art) are shown in
FIG. 1 . - HUVEC cells (Clonetics) were cultured with EGM-2 media (Clonetics) in T-175 flasks. 1×107 cells were collected and subjected to the total RNA extraction using the RNA purification kit from Qiagen, and then cDNA was synthesized using the Invitrogen cDNA kit. The cDNA product was stored at −80° C. until usage.
- PCR utilizing specific primers were used to amplify various FLT-1 and KDR domains from the HUVEC cDNA. Likewise, PCR utilizing specific primers from Lymph Nodes cDNA (BD Clontech) were used to amplify human IgG1 Fc was PCR.
- Primers:
-
for FLT-1 d2 forward: 5′-cctttcgtagagatgtacagtga-3′; (SEQ ID NO: 8) for FLT-1 d2 reverse: 5′-tatgattgtattggtttgtccat-3′; (SEQ ID NO: 9) for KDR d3-4 forward: 5′-gatgtggttctgagtccgtctca-3′; (SEQ ID NO: 10) for KDR d3-4 reverse: 5′-cggtgggacatacacaaccaga-3′; (SEQ ID NO: 11) for human IgG1 Fc forward: 5′-gacaaaactcacacatgcccact-3′; (SEQ ID NO: 12) and for human IgG1 Fc reverse: 5′-tcatttacccggagacagggagag-3′. (SEQ ID NO: 13) - The Ig-like domains and the human IgG1 Fc fragment were PCR amplified at conditions of denaturing at 95° C. for 30 seconds, annealing at 56° C. for 45 seconds, extension at 72° C. for 2 minutes, and 30 cycles. The PCR products were then cloned into plasmid pCR2.1 (Invitrogen) using the TA cloning kit. After transformation into E.coli (JM109), white colonies were picked and cultured overnight in LB media. DNA plasmids were prepared using the Qiagen kit and subjected to enzyme digestion and DNA sequencing.
- The cDNAs of FLT-1, KDR and IgG Fc were fused together by sewing PCR using primers containing the EcoRI site. After digestion with EcoRI, the DNA fragment was purified with the Qiagen purification kit and cloned into plasmid pcDNA3.1. After transformed into E. coli (JM109), positive colonies were picked and cultured overnight in LB media. DNA plasmids were extracted with the Qiagen plasmid purification kit and then subjected to enzyme digestion and DNA sequencing. The obtained FP3′ DNA coding sequence is shown as SEQ ID NO.6. The confirmed plasmids were used to transfect 293 cells or CHO cells to obtain stable cell lines expressing FP3′. The amino acid sequence of FP3′ is shown as SEQ ID NO.7.
- FP1′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP2′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 1st Ig-like domain of KDR, the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP4′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, the 4th Ig-like domain of FLT-1, and the same human IgG1 Fc as in Example 1.
- FP5′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2nd Ig-like domain of FLT-1, the 3rd-5th Ig-like domain of KDR, and the same human IgG1 Fc as in Example 1.
- FP6′ was constructed similarly as in Example 1. The only difference was that the targeted recombinant DNA was constructed by fusing together the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, the 4th-5th Ig-like domain of FLT-1, and the same human IgG1 Fc as in Example 1.
- After construction of above-mentioned recombinant plasmids, high quality plasmid DNAs were obtained using Qiagen's plasmid kit, and then were transfected into 293 cells (ATCC) using FUGEN6 transfection kit (Roche). Two different methods were used to express the chimeric proteins depending on amount of proteins needed.
- The first method was a method of transient transfection. A small amount of the chimeric proteins were produced using this method. Firstly, 293 cells were cultured in DMEM media with 10% FBS in tissue culture dishes. At 60-80% cell confluence, the mixture of plasmid DNA and FUGEN6 reagent was added into the culture. The culture media was exchanged to serum-free DMEM in the next day and the cells were continued to culture for 3 more days before media was collected. These media contained the expressed chimeric proteins, and the concentration of the chimeric proteins was assayed by ELISA.
- The second method was a method of stable transfection. A stable cell line was established to produce a large amount of the chimeric proteins. The host cells were again 293 cells (ATCC). The step of transfecting recombinant plasmid was the same as that of transient transfection described above. However, at the 2nd day, the cells were cultured in DMEM with neomycin and cloned by limited dilution. After about 21 days, neomycin resistant clones were picked and cultured in a larger scale. Finally, chimeric proteins were expressed in shaker flasks. The concentration of chimeric proteins was assayed by ELISA.
- FP3′ was purified from the cultured media using assays including affinity chromatography and gel filtration, etc. The molecular weight of FP3′ was 140 KD.
- Chimeric proteins FP1′, FP2′, FP4′, FP5′, and FP6′ were obtained in accordance with the methods of example 7.
- Affinities of the chimeric proteins to VEGF were determined by the VEGF binding assay in the present invention. Firstly, recombinant VEGF proteins (Chemicom) were coated in a 96-well ELISA plate, and non-specific protein binding sites of the plate were then blocked using 5% milk solution. Secondly, different concentrations of various chimeric proteins were added into each well, and incubated for 2 hours at 37° C. After washing, rabbit anti-human Ig-HRP (Sigma) was added into each well, and finally colorimetric enzyme substrates were added to the plate. The absorption OD readings were recorded with the use of an ELISA plate reader. A higher OD value indicated a stronger binding affinity of the chimeric proteins to VEGF.
- As shown in
FIG. 2 , all five chimeric proteins constructed and expressed in the embodiments of the present invention were able to bind VEGF, and had better affinities than FP1′ of the prior art. The binding was detectable at low concentrations of 1 μg/ml. Preferably, FP3′ had the best affinity and was the best VEGF inhibitor. Its half maximal binding concentration was about 5 times lower than that of FP1′. FP5′ had a little bit lower affinity to VEGF than that of FP3′. This result suggests that the 4th Ig-like domain of KDR could substantially increase the blocking activity of the chimeric protein to VEGF. However, adding more of the KDR domains such as the 5th Ig-like domain could not further enhance the inhibitory effect on VEGF. The other three chimeric proteins exhibited lower affinities comparing to FP3′ and FP5′, but higher affinities than FP1′. - This preferred embodiment of the invention is to prove that the chimeric proteins could effectively block VEGF-induced growth of vascular endothelial cells. In the experiment, HUVEC cells (Clonetics) were seeded in a 96-well tissue culture plate in EBM media with 2% FBS and 15 ng/ml of VEGF. Different amounts of the 293 cells supernatant containing the chimeric proteins were added into the plate. Un-transfected 293 cells media containing no chimeric proteins was used as negative control. All HUVEC cells were cultured in 37° C. for 3 days before cell densities were determined by cell counting.
- The HUVEC proliferation experiment has shown that all five chimeric proteins constructed according to the invention could inhibit proliferation of vascular endothelial cells more effectively than FP1′ of the prior art (
FIG. 3 ). Since the HUVEC cell proliferation in the experiment was induced by VEGF activation, it is therefore suggested that all five chimeric proteins were able to inhibit the receptor activation of VEGF, and all of them possessed anti-angiogenesis activities. Among which, FP3′ had the best inhibiting effect on the HUVEC cell growth with IC50 of about 3 ng/ml. The IC50 of FP1′ of the prior art was about 12 ng/ml, and the IC50s of FP2′, FP4′, FP5′ and PF6′ were all about 5-8 ng/ml. - The injection formulation was prepared according to any conventional methodologies, for injection formulations using 24 mg/ml of FP3′, 5 mM of PB, 100 mM of NaCl, and 20% sucrose.
- As VEGF inhibitors, one application of the chimeric proteins of the invention is to be used in anti-cancer therapy. Because of its highly effective blocking effect on VEGF, FP3′ was chosen to perform anti-tumor experiments in animal models.
- The animal model was murine with B16F10 melanoma cells which is a kind of rapidly growing tumor cells. In the experiment, 1×105 B16F10 cells in 0.05 ml were first injected subcutaneously in the back of BALB/C nude mice. Then the purified chimeric protein was injected intraperitomneally with 400 μg each mouse (mice average weight 22 g), twice a week. Same amount of the purified human immunoglobulin Fc was injected into negative control mice. Tumor growth curves were shown in
FIG. 4 , indicating that the chimeric protein FP3′ effectively inhibited the growth of the melanoma cells (P<0.01). - Xenograft model of human tumor cells growing in nude mice is one of the animal models, which is most similar with human tumors. Nude mice lack of immune rejection, thus many human tumor cells could grow in nude mice and form tumor. The chimeric protein FP3′ was tested for inhibiting growth of human prostate tumor PC-3 cells (ATCC) in BALB/C nude mice. In this model, 1×105 PC-3 cells in 0.05 ml were first injected subcutaneously in the back of mice. Then the purified chimeric protein was injected intraperitomneally with 400 μg each mouse, twice a week. Same amount of the purified human immunoglobulin Fc was injected into negative control mice. The experimental results were shown in
FIG. 5 . In the control mice, tumor grew more than 1000mm 3 45 days after implantation. However, in the mice administered with the chimeric proteins, FP3′ has almost completely inhibited the tumor growth (P<0.01), demonstrating a significant therapeutic anti-tumor effect. - In order to further demonstrate the supreme anti-cancer activity of FP3′, the effects of FP1′ and FP3′ were compared in a tumor growth experiment. 10 healthy BALB/C nude mice were chosen and each was injected subcutaneously in the back with 1×105 rat glioblastoma C6 cells in 0.05 ml. Then 2.5 mg/kg of purified PF1′ or PF3′ were injected intraperitomneally twice a week, respectively, up to 31 days. The same amount of the purified human immunoglobulin Fc was injected into negative control mice. The experimental results are shown in
FIG. 6 . FP1′ and FP3′ both had a significant therapeutic effect on the tumor. Atday 35, tumor volumes of mice administered with FP1′ and FP3′ were 1167.3 and 557.6, respectively, whereas tumor volume of the control mice treated with Fc has already reached 1312.3 atday 24. Therefore, FP3′ had more significant effect (P<0.05) than FP1′ of the prior art. - All taken together, the chimeric proteins constructed according to the invention had a high affinity to VEGF, were able to inhibit vascular endothelial cell proliferation in vitro, and effectively inhibited tumor growth in vivo. Since angiogenesis is critical in all tumor growth, the chimeric proteins of the invention can be used in therapeutic applications against many tumors.
Claims (10)
1. A type of chimeric proteins consisting of different fragments of the VEGF receptors FLT-1 and KDR, characterized in that the chimeric proteins are selected from the following groups :
a. consisting of the 2nd Ig-like domain of FLT-1, and the 3rd and the 4th Ig-like domains of KDR, designated as FLTd2-KDRd3,4;
b. consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th Ig-like domain of FLT-1, designated as FLTd2-KDRd3-FLTd4;
c. consisting of the 2nd Ig-like domain of FLT-1, and the 3 rd, the 4th and the 5th Ig-like domains of KDR, designated as FLTd2-KDRd3,4,5;
d. consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th and the 5th Ig-like domains of FLT-1, designated as FLTd2-KDRd3-FLTd4,5.
2. A type of chimeric proteins consisting of the chimeric proteins of claim 1 and human immunoglobulin Fe, which are selected from the following groups:
FP4′ designated as FLTd2-KDRd3-FLTd4-Fc;
FP5′ designated as FLTd2-KDRd3,4,5-Fc;
FP6′ designated as FLTd2-KDRd3-FLTd4,5-Fc.
3. The chimeric proteins of claim 2 , wherein the immunoglobulin Fc is derived from classes or subclasses of human immunoglobulin.
4. The chimeric proteins of claim 3 , wherein the immunoglobulin Fc fragment is a full length Fc or a fragment of Fc sequence.
5. An isolated recombinant DNA coding sequence encoding a chimeric protein, comprising fragments of the VEGF receptors FLT-1 and KDR, and optionally Immunoglobulin Fc, wherein the chimeric protein is selected from the group consisting of:
a. a chimeric protein consisting of the 2nd Ig-like domain of FLT-1, and the 3rd and 4th Ig-like domains of KDR, designated as FLTd2-KDRd3,4;
b. a chimeric protein consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th Ig-like domain of FLT-1, designated as FLTd2-KDRd3-FLTd4;
c. a chimeric protein consisting of the 2nd Ig-like domain of FLT-1, and the 3rd, 4th and 5th Ig-like domains of KDR, designated as FLTd2-KDRd3,4,5;
d. a chimeric protein consisting of the 2nd Ig-like domain of FLT-1, the 3rd Ig-like domain of KDR, and the 4th and the 5th Ig-like domains of FLT-1, designated as FLTd2-KDRd3 -FLTd4, 5;
e. FP4′ designated as FLTd2-KDRd3-FLTd4-Fc;
f. FP5′ designated as FLTd2-KDRd3-FLTd4-Fc; and
g. FP6′ designated as FLTd2-KDRd3-FLTd4,5-Fc.
6. An isolated recombinant vector comprising the recombinant DNA sequences of claim 5 , wherein the vector is selected from plasmid, virus, or DNA fragment.
7. An isolated recombinant host cell containing the recombinant vector of claim 6 , wherein the host cell is a eukaryotic cell or prokaryotic cell.
8. A pharmaceutical composition which comprises one or more chemeric proteins encoded by the recombinant DNA according to claim 5 and a pharmaceutical acceptable carrier.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is an injection solution.
10. A method of treating an angiogenesis-related disease in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 8 , wherein the disease is selected from the group consisting of a tumor, a diabetic retinopathies, arthritis, anemia and endometrial hyperplasia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/773,315 US20100215655A1 (en) | 2004-06-08 | 2010-05-04 | Angiogenesis-inhibiting chimeric proteins and the use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410044965 | 2004-06-08 | ||
CN200410044965.7 | 2004-06-08 | ||
PCT/CN2005/000802 WO2005121176A1 (en) | 2004-06-08 | 2005-06-08 | Angiogenesis-inhibiting chimeric protein and the use |
US62873506A | 2006-12-07 | 2006-12-07 | |
US12/773,315 US20100215655A1 (en) | 2004-06-08 | 2010-05-04 | Angiogenesis-inhibiting chimeric proteins and the use |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/000802 Division WO2005121176A1 (en) | 2004-06-08 | 2005-06-08 | Angiogenesis-inhibiting chimeric protein and the use |
US62873506A Division | 2004-06-08 | 2006-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100215655A1 true US20100215655A1 (en) | 2010-08-26 |
Family
ID=35503012
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/628,735 Active 2026-10-04 US7750138B2 (en) | 2004-06-08 | 2005-06-08 | Angiogenesis-inhibiting chimeric protein and the use |
US12/773,315 Abandoned US20100215655A1 (en) | 2004-06-08 | 2010-05-04 | Angiogenesis-inhibiting chimeric proteins and the use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/628,735 Active 2026-10-04 US7750138B2 (en) | 2004-06-08 | 2005-06-08 | Angiogenesis-inhibiting chimeric protein and the use |
Country Status (13)
Country | Link |
---|---|
US (2) | US7750138B2 (en) |
EP (1) | EP1767546B1 (en) |
JP (1) | JP4680997B2 (en) |
KR (1) | KR100897379B1 (en) |
AT (1) | ATE548384T1 (en) |
BR (1) | BRPI0512286B8 (en) |
CA (1) | CA2569108C (en) |
DK (1) | DK1767546T3 (en) |
ES (1) | ES2381014T3 (en) |
PL (1) | PL1767546T3 (en) |
PT (1) | PT1767546E (en) |
RU (1) | RU2355414C2 (en) |
WO (1) | WO2005121176A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN100502945C (en) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Application of fusion protein of VEGF receptor for treating disease of eye |
HUE053612T2 (en) | 2006-06-16 | 2021-07-28 | Regeneron Pharma | Vegf antagonist formulations suitable for intravitreal administration |
CN101838329A (en) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | Anti-angiogenesis fusion protein |
KR101248912B1 (en) * | 2009-12-31 | 2013-03-29 | 한양대학교 산학협력단 | Recombinant Adenovirus Having Anti―Angiogenesis Activity |
KR20180023015A (en) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | Use of a vegf antagonist to treat angiogenic eye disorders |
PL3679922T3 (en) | 2012-06-01 | 2022-01-03 | Novartis Ag | Syringe |
DE202012011016U1 (en) | 2012-07-03 | 2012-11-28 | Novartis Ag | Aflibercept syringe |
JOP20200175A1 (en) | 2012-07-03 | 2017-06-16 | Novartis Ag | Syringe |
AR095196A1 (en) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | SERUM FREE CELL CULTIVATION MEDIA |
WO2014203183A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating macular edema |
US20160129080A1 (en) | 2013-06-20 | 2016-05-12 | Aaron Osborne | Treatment of polypoidal chroidal vasculopathy |
JP2016522249A (en) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | Use of VEGF antagonists in the treatment of choroidal neovascularization |
WO2015004616A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
BR112016000546A2 (en) | 2013-07-12 | 2017-11-21 | Ophthotech Corp | methods to treat or prevent eye conditions |
BR112016015187A2 (en) * | 2014-01-25 | 2018-06-05 | Chengdu Kanghong Biotechnologies Co., Ltd | A method of inhibiting angiogenesis, or the growth of fusion proteins and their use |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
BR112017027567A2 (en) | 2015-06-28 | 2018-09-04 | Allgenesis Biotherapeutics Inc. | fusion proteins to inhibit angiogenesis |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN115951066A (en) | 2016-02-29 | 2023-04-11 | 麦恩泰科特有限公司 | Predictive markers useful for the treatment of wet age-related macular degeneration |
JP7244442B2 (en) | 2017-06-08 | 2023-03-22 | ノバルティス アーゲー | Injection device and injection solution transfer system |
TW201904610A (en) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | Non-antibody vegf antagonists for the treatment of neovascular glaucoma |
SG11202001647UA (en) * | 2017-06-30 | 2020-03-30 | Korea Advanced Inst Sci & Tech | Conjugate of vegf-grab protein and drug, and use thereof |
EP3649144A4 (en) | 2017-07-06 | 2021-07-21 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
CN116585466A (en) | 2018-05-10 | 2023-08-15 | 瑞泽恩制药公司 | Formulations containing high concentrations of VEGF receptor fusion proteins |
US20220332792A1 (en) * | 2019-09-04 | 2022-10-20 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
WO2022051537A1 (en) * | 2020-09-03 | 2022-03-10 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20230057380A1 (en) * | 2019-11-26 | 2023-02-23 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
JP2023506180A (en) | 2019-12-12 | 2023-02-15 | ノバルティス アーゲー | Injection device and injection solution transfer system |
EP4182025A1 (en) | 2020-07-16 | 2023-05-24 | Novartis AG | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
BR112023023002A2 (en) | 2021-05-17 | 2024-01-23 | Bayer Healthcare Llc | EXTENDED REGIMES OF HIGH-DOSE VEGF ANTAGONISTS FOR TREATMENT OF ANGIOGENIC EYE DISEASES |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
WO2023177689A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
US20240024420A1 (en) | 2022-03-15 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057428A (en) * | 1995-08-25 | 2000-05-02 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20050196396A1 (en) * | 2003-11-10 | 2005-09-08 | Greenville Hospital System | VEGF receptor antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434115T2 (en) * | 1993-03-25 | 2005-10-27 | Merck & Co., Inc. | INHIBITOR OF THE GROWTH FACTOR FOR VITAL TREATMENT CELLS |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
ATE417928T1 (en) * | 1999-06-08 | 2009-01-15 | Regeneron Pharma | VEGF RECEPTOR CHIMERAS FOR THE TREATMENT OF EYE DISEASES CHARACTERIZED BY VASCULAR PERMEABILITY. |
CN101134777A (en) * | 2006-08-31 | 2008-03-05 | 苏州思坦维生物技术有限责任公司 | Method for preparing humanized immune globulin capable of antagonizing vessel endothelium cell growth factor and combined uses thereof |
-
2005
- 2005-06-08 EP EP05752254A patent/EP1767546B1/en active Active
- 2005-06-08 DK DK05752254.2T patent/DK1767546T3/en active
- 2005-06-08 ES ES05752254T patent/ES2381014T3/en active Active
- 2005-06-08 PL PL05752254T patent/PL1767546T3/en unknown
- 2005-06-08 BR BRPI0512286A patent/BRPI0512286B8/en active IP Right Grant
- 2005-06-08 US US11/628,735 patent/US7750138B2/en active Active
- 2005-06-08 CA CA2569108A patent/CA2569108C/en active Active
- 2005-06-08 JP JP2007526176A patent/JP4680997B2/en active Active
- 2005-06-08 PT PT05752254T patent/PT1767546E/en unknown
- 2005-06-08 RU RU2006146995/15A patent/RU2355414C2/en active
- 2005-06-08 AT AT05752254T patent/ATE548384T1/en active
- 2005-06-08 KR KR1020067026641A patent/KR100897379B1/en active IP Right Grant
- 2005-06-08 WO PCT/CN2005/000802 patent/WO2005121176A1/en active Application Filing
-
2010
- 2010-05-04 US US12/773,315 patent/US20100215655A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057428A (en) * | 1995-08-25 | 2000-05-02 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20050196396A1 (en) * | 2003-11-10 | 2005-09-08 | Greenville Hospital System | VEGF receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
PT1767546E (en) | 2012-03-20 |
CA2569108A1 (en) | 2005-12-22 |
EP1767546B1 (en) | 2012-03-07 |
JP2008503243A (en) | 2008-02-07 |
RU2006146995A (en) | 2008-07-20 |
EP1767546A4 (en) | 2008-03-19 |
RU2355414C2 (en) | 2009-05-20 |
CA2569108C (en) | 2012-08-21 |
KR100897379B1 (en) | 2009-05-14 |
US20080206238A1 (en) | 2008-08-28 |
ES2381014T3 (en) | 2012-05-22 |
KR20070029204A (en) | 2007-03-13 |
BRPI0512286B1 (en) | 2020-03-24 |
BRPI0512286A (en) | 2008-03-18 |
EP1767546A1 (en) | 2007-03-28 |
US7750138B2 (en) | 2010-07-06 |
BRPI0512286B8 (en) | 2021-05-25 |
DK1767546T3 (en) | 2012-04-23 |
PL1767546T3 (en) | 2012-07-31 |
WO2005121176A1 (en) | 2005-12-22 |
ATE548384T1 (en) | 2012-03-15 |
JP4680997B2 (en) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750138B2 (en) | Angiogenesis-inhibiting chimeric protein and the use | |
JP5952847B2 (en) | Fusion proteins that bind growth factors | |
US8926972B2 (en) | Anti-angiogenesis fusion proteins | |
EP3705498A1 (en) | Tgf-beta receptor type ii variants and uses thereof | |
EP3072519A1 (en) | Peptide having angiogenesis inhibitory activity and composition containing same | |
AU2011239839B2 (en) | Robo1-Fc fusion protein and use thereof for treating tumours | |
KR20130004568A (en) | Inhibition of axl signaling in anti-metastatic therapy | |
EP1297013B1 (en) | Use of taci as an anti-tumor agent | |
WO2007058776A2 (en) | Hepatocyte growth factor intron fusion proteins | |
HU227008B1 (en) | Use of baff receptor (bcma) as an immunoregulatory agent | |
CN108430511B (en) | Drug design method, obtained drug and application thereof | |
EA004793B1 (en) | Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof | |
EA013967B1 (en) | Conjugation product | |
CN102470156A (en) | Polypeptides selective for av ss3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof | |
AU2001253920A1 (en) | Use of taci as an anti-tumor agent | |
EP2655408B1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
CN101553501A (en) | IL-21 variants | |
CN101914161B (en) | Fusion protein HGF alpha-Fc for restraining tumor growth and application thereof | |
KR20080002213A (en) | Polypeptides or fusion proteins thereof having an inhibitory activity against growth and metastasis of cancer cells | |
EP1746106A2 (en) | Use of TACI as an anti-tumor agent | |
WO2003060075A2 (en) | USE OF SOLUBLE TYPE II TGF-β RECEPTOR TO SUPPRESS PANCREATIC CANCER GROWTH AND METASTASIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |